Study on the Safety of Drug BAY2586116 and How it Works in Patients With Obstructive Sleep Apnea (a Sleep Disorder Caused by the Narrowing and Collapse of the Airway During Sleep) Including the Blood Level of the Drug and Effect of Its Doses and Routes of Administration
Condition: Sleep Apnea, Obstructive Interventions: Drug: BAY2586116 (A1); Drug: Placebo (A2); Drug: BAY2586116 (B1); Drug: BAY2586116 (B2); Drug: BAY2586116 (B3) Sponsor: Bayer Not yet recruiting
This is the first study to comprehensively measure both anatomical and non ‐anatomical OSA traits during sleep in those with COPD + OSA (Overlap syndrome) and compare them to those with OSA alone. No consistent differences were found between the two groups, while worsened lung function did impact upper airway function and control of breathing. These findings have impli cations towards mechanisms underlying OSA, as well as management of sleep apnea. AbstractOverlap syndrome (OVS) is the concurrence of chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA), and is associated with poor outc...
We report our experience in developing a perioperative multidisciplinary intervention of reintroducing PAP therapy to nonadherent OSA patients with the intent of motivating patients to return to their outpatient sleep medicine clinics.
Authors: Uesugi S, Imamura T, Yonemitsu I, Ono T PMID: 32053499 [PubMed - in process]
ConclusionThis systematic review describes swallowing function in patients with OSAS. However, due to the variability in defining OSAS and dysphagia, in the assessment method used to determine dysphagia, and heterogeneity of study designs, true prevalence is difficult to determine. Clinicians involved in the management of OSAS patients should employ validated assessment measures to determine if swallow dysfunction is present.
Our aim was to explore the influence of sleep and circadian preference on upper extremity (UE) rehabilitation in stroke patients after constraint-induced movement therapy (CIMT) in a cross-sectional retrospective observational study. Forty-three patients were selected to complete questionnaires on circadian preference, sleep quality, excessive daytime sleepiness, and risk of obstructive sleep apnea. They had undergone a 10-day standard CIMT program without medical complications and with normal to minimal cognitive dysfunction. All pre- and postrehabilitation scores (patient perception of the quantity and quality of use of ...
ConclusionsThe MVA incidence did not change after CPAP treatment. Among the patients who had MVA, BMI was the only baseline characteristic that differed between the groups and tended to further increase after CPAP treatment. Differences in sleep study data or accident conditions were not observed.
Journal of Clinical Sleep Medicine, Ahead of Print.
CONCLUSIONS: The MVA incidence did not change after CPAP treatment. Among the patients who had MVA, BMI was the only baseline characteristic that differed between the groups and tended to further increase after CPAP treatment. Differences in sleep study data or accident conditions were not observed. PMID: 32060778 [PubMed - as supplied by publisher]
In conclusion, a 6-month CPAP treatment did not reduce aortic stiffness, measured by cf-PWV, in patients with RHT and moderate/severe OSA, but treatment may prevent its progression, in contrast to no-CPAP therapy. PMID: 32048379 [PubMed - as supplied by publisher]
Pompe disease (PD), also known as glycogen-storage disease type II or acid-maltase deficiency, is an orphan disease characterized by deficient acid alfa-glucosidase (GAA) enzyme activity, resulting in a metabolic myopathy from the accumulation of intracellular glycogen . The estimated incidence ranges from 1 in 40,000 to 1 in 300,000 live births and varies with region and race . Of the many complications of the late-onset form of PD (LOPD), obstructive sleep apnea (OSA) is relatively common with studies showing prevalence rates of approximately 20% .